Latest Blog Posts Tagged "Industry"
March 19, 2018
Acquisitions can bring experience and funds to move Parkinson's therapies through testing and to patient hands faster.
October 03, 2016
Dale B. Schenk, PhD, a leader in the movement to treat neurodegenerative diseases with antibodies, died September 30.
August 14, 2015
Neuropore Therapies and Biogen grow the field of clinical trials with approaches against alpha-synuclein, our most promising target for a therapy to slow or stop Parkinson's progression.
July 29, 2015
Drugs in development that go after the processes, rather than the proteins, involved in Alzheimer's onset may have potential to treat Parkinson's disease, as well.
July 21, 2015
Pfizer video highlights collaboration with The Michael J. Fox Foundation.
February 04, 2015
The Foundation has united three powerhouse pharmaceutical companies for a pre-competitive consortium to advance LRRK2 inhibitors as potential disease-modifying medications.
September 24, 2014
In the last few weeks many MJFF-funded companies have announced investments and partnerships that will help usher their projects through development to patients' hands.
June 02, 2014
Scientific Advisor Jennifer Johnston, PhD, is the recipient of the 2014 James William Langston Award for her insight and advice in support of our mission to cure Parkinson's disease.
March 24, 2014
The Parkinson's Action Network, MJFF and other PD organizations respond to PhRMA report on Parkinson's drugs in the development pipeline.
February 10, 2014
Johnson & Johnson is the latest pharmaceutical company to open access to its clinical trial data. MJFF has been a leader in the movement to disclose data to speed discovery and development.